This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter revenue Rs 449.66 crore, net profit Rs 51.63 crore, down year on year
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated results for the quarter ended September 30, 2026: revenue was Rs 449.66 crore and profit after tax Rs 51.63 crore, down 12.6% and 46.7%, respectively, from Rs 514.27 crore and Rs 96.85 crore a year earlier. Consolidated half-year revenue was Rs 1,091.23 crore, profit after tax Rs 199.30 crore and operating cash flow Rs 109.45 crore. The board approved Rs 47.1 crore for land for future expansion, funded by internal accruals.
Revenue and profit fell and operating margin narrowed, likely pressuring sentiment; positive cash flow and expansion support long-term outlook.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹449.7 Cr | ₹514.3 Cr | −12.6% |
| Operating profit | ₹61.48 Cr | ₹127.6 Cr | −51.8% |
| Profit after tax | ₹51.63 Cr | ₹96.85 Cr | −46.7% |
| EBITDA margin | 21.7% | 30.3% | −8.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.